{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:51:30Z","timestamp":1769187090739,"version":"3.49.0"},"reference-count":35,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.3892\/or.2012.2214","type":"journal-article","created":{"date-parts":[[2012,12,28]],"date-time":"2012-12-28T10:17:54Z","timestamp":1356689874000},"page":"1133-1139","source":"Crossref","is-referenced-by-count":7,"title":["Suppression of HER-2 via siRNA interference promotes apoptosis and decreases metastatic potential of SKOV-3 human ovarian carcinoma cells"],"prefix":"10.3892","volume":"29","author":[{"given":"YAN-MING","family":"LU","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MENG-LI","family":"RONG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHAO","family":"SHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NING","family":"WANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XIANG","family":"LI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YAN-YAN","family":"ZHAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHU-LAN","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2012,12,28]]},"reference":[{"key":"key20180107213917_b1-or-29-03-1133","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"key20180107213917_b2-or-29-03-1133","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"key20180107213917_b3-or-29-03-1133","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J"},{"key":"key20180107213917_b4-or-29-03-1133","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","article-title":"Critical update and emerging trends in epidermal growth factor receptor targeting in cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107213917_b5-or-29-03-1133","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20180107213917_b6-or-29-03-1133","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"key20180107213917_b7-or-29-03-1133","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.2011-0212","article-title":"Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy","volume":"17","author":"Duchnowska","year":"2012","journal-title":"Oncologist"},{"key":"key20180107213917_b8-or-29-03-1133","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1940-6207.CAPR-11-0334","article-title":"Targeting the HER\/EGFR\/ErbB family to prevent breast cancer","volume":"4","author":"Howe","year":"2011","journal-title":"Cancer Prev Res"},{"key":"key20180107213917_b9-or-29-03-1133","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/CAD.0b013e3283330590","article-title":"Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities","volume":"20","author":"Modjtahedi","year":"2009","journal-title":"Anticancer Drugs"},{"key":"key20180107213917_b10-or-29-03-1133","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ctrv.2006.01.001","article-title":"Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer","volume":"32","author":"Serrano-Olvera","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"key20180107213917_b11-or-29-03-1133","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0002-9378(12)90907-2","article-title":"Prognostic significance of HER-2\/neu expression in advanced epithelial ovarian cancer: a multivariate analysis","volume":"168","author":"Rubin","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"key20180107213917_b12-or-29-03-1133","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"key20180107213917_b13-or-29-03-1133","doi-asserted-by":"crossref","first-page":"217","DOI":"10.18388\/abp.2003_3730","article-title":"RNA interference and its role in the regulation of eucaryotic gene expression","volume":"50","author":"Szweykowska-Kuli\u0144ska","year":"2003","journal-title":"Acta Biochim Pol"},{"key":"key20180107213917_b14-or-29-03-1133","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"key20180107213917_b15-or-29-03-1133","first-page":"250","article-title":"E1A-mediated paclitaxel sensitization in HER-2\/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway","volume":"6","author":"Ueno","year":"2000","journal-title":"Clin Cancer Res"},{"key":"key20180107213917_b16-or-29-03-1133","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"key20180107213917_b17-or-29-03-1133","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1126\/science.7878464","article-title":"Apoptosis in the pathogenesis and treatment of disease","volume":"267","author":"Thompson","year":"1995","journal-title":"Science"},{"key":"key20180107213917_b18-or-29-03-1133","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.canlet.2011.06.007","article-title":"Magnolol down-regulates HER2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells","volume":"311","author":"Chuang","year":"2011","journal-title":"Cancer Lett"},{"key":"key20180107213917_b19-or-29-03-1133","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1158\/1078-0432.CCR-10-2927","article-title":"Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models","volume":"17","author":"Yamashita-Kashima","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107213917_b20-or-29-03-1133","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1038\/onc.2011.111","article-title":"Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification","volume":"30","author":"Tanizaki","year":"2011","journal-title":"Oncogene"},{"key":"key20180107213917_b21-or-29-03-1133","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1582-4934.2011.01302.x","article-title":"Matrix metalloproteinases: protective roles in cancer","volume":"15","author":"Decock","year":"2011","journal-title":"J Cell Mol Med"},{"key":"key20180107213917_b22-or-29-03-1133","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1007\/s00018-011-0763-x","article-title":"Matrix metalloproteinases in tumorigenesis: an evolving paradigm","volume":"68","author":"Hua","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"key20180107213917_b23-or-29-03-1133","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/hed.21277","article-title":"Expression of matrix metalloproteinase-1, -7, -9, -13, Ki-67, and HER-2 in epithelial- myoepithelial salivary gland cancer","volume":"32","author":"Luukkaa","year":"2010","journal-title":"Head Neck"},{"key":"key20180107213917_b24-or-29-03-1133","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.canlet.2008.10.013","article-title":"Overexpression of ErbB2 induces invasion of MCF10A human breast epithelial cells via MMP-9","volume":"275","author":"Kim","year":"2009","journal-title":"Cancer Lett"},{"key":"key20180107213917_b25-or-29-03-1133","first-page":"1199","article-title":"Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities","volume":"57","author":"Tan","year":"1997","journal-title":"Cancer Res"},{"key":"key20180107213917_b26-or-29-03-1133","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.addr.2011.02.003","article-title":"Target cell movement in tumor and cardiovascular diseases based on the epithelial-mesenchymal transition concept","volume":"63","author":"Chua","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"key20180107213917_b27-or-29-03-1133","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1593\/tlo.10244","article-title":"Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma","volume":"4","author":"Sethi","year":"2011","journal-title":"Transl Oncol"},{"key":"key20180107213917_b28-or-29-03-1133","first-page":"439","article-title":"c-erbB2-induced epithelial-mesenchymal transition in mammary epithelial cells is suppressed by cell-cell contact and initiated prior to E-cadherin downregulation","volume":"27","author":"Jenndahl","year":"2005","journal-title":"Int J Oncol"},{"key":"key20180107213917_b29-or-29-03-1133","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/0008-5472.CAN-08-3612","article-title":"Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis","volume":"69","author":"Ricono","year":"2009","journal-title":"Cancer Res"},{"key":"key20180107213917_b30-or-29-03-1133","doi-asserted-by":"crossref","first-page":"C1532","DOI":"10.1152\/ajpcell.00478.2005","article-title":"Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium","volume":"290","author":"Ahmed","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"key20180107213917_b31-or-29-03-1133","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1158\/0008-5472.CAN-07-2460","article-title":"Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells","volume":"68","author":"Fuchs","year":"2008","journal-title":"Cancer Res"},{"key":"key20180107213917_b32-or-29-03-1133","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrc822","article-title":"Epithelial-mesenchymal transitions in tumour progression","volume":"2","author":"Thiery","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"key20180107213917_b33-or-29-03-1133","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2009.09.017","article-title":"Epithelial-mesenchymal transition in ovarian cancer","volume":"291","author":"Vergara","year":"2010","journal-title":"Cancer Lett"},{"key":"key20180107213917_b34-or-29-03-1133","first-page":"909","article-title":"Influence of human epidermal growth factor receptor-2 siRNA on chemosensitivity to cisplatin of human ovarian carcinoma cells: an in vitro experiment","volume":"88","author":"Lu","year":"2008","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"key20180107213917_b35-or-29-03-1133","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00210-004-1016-4","article-title":"Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells","volume":"371","author":"Abuharbeid","year":"2005","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2012.2214\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T13:35:05Z","timestamp":1595165705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2012.2214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,28]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,12,28]]},"published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.3892\/or.2012.2214"],"URL":"https:\/\/doi.org\/10.3892\/or.2012.2214","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,28]]}}}